520 related articles for article (PubMed ID: 30449789)
21. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
[TBL] [Abstract][Full Text] [Related]
25. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
27. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Gil B; Merav L; Pnina L; Chagai G
Clin Rheumatol; 2016 Aug; 35(8):2125-2130. PubMed ID: 25846833
[TBL] [Abstract][Full Text] [Related]
29. Interstitial Lung Disease with Anti-melanoma Differentiation-associated Protein 5 Antibody: Rapidly Progressive Perilobular Opacity.
Chino H; Sekine A; Baba T; Kitamura H; Iwasawa T; Okudela K; Takemura T; Itoh H; Sato S; Suzuki Y; Ogura T
Intern Med; 2019 Sep; 58(18):2605-2613. PubMed ID: 31178482
[TBL] [Abstract][Full Text] [Related]
30. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.
Gono T; Tanino Y; Nishikawa A; Kawamata T; Hirai K; Okazaki Y; Shibata Y; Kuwana M
Int J Rheum Dis; 2019 Aug; 22(8):1582-1586. PubMed ID: 31050194
[TBL] [Abstract][Full Text] [Related]
31. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
32. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2012 Aug; 22(4):625-9. PubMed ID: 22124544
[TBL] [Abstract][Full Text] [Related]
33. Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
Matsumoto H; Sato S; Fujita Y; Yashiro-Furuya M; Matsuoka N; Asano T; Kobayashi H; Watanabe H; Migita K
Intern Med; 2019 Mar; 58(5):737-742. PubMed ID: 30333415
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of plasma exchange for anti-MDA5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series.
Watanabe T; Taniguchi M; Ogura S; Asou M; Takayanagi S; Sokai Y; Tsuji Y; Mori KP; Endo T; Nakajima T; Imura Y; Tsukamoto T
Ther Apher Dial; 2024 Jun; 28(3):432-441. PubMed ID: 38225794
[TBL] [Abstract][Full Text] [Related]
35. An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.
Sato Y; Otsuka K; Tamai K; Ono Y; Hamaguchi Y; Tomii K
Intern Med; 2017; 56(3):341-346. PubMed ID: 28154280
[TBL] [Abstract][Full Text] [Related]
36. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
Ikeda S; Arita M; Morita M; Ikeo S; Ito A; Tokioka F; Noyama M; Misaki K; Notohara K; Ishida T
BMC Pulm Med; 2015 Dec; 15():159. PubMed ID: 26651481
[TBL] [Abstract][Full Text] [Related]
37. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
38. Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms.
Tamai K; Tachikawa R; Otsuka K; Ueda H; Hosono Y; Tomii K
Intern Med; 2014; 53(21):2515-9. PubMed ID: 25366013
[TBL] [Abstract][Full Text] [Related]
39. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
40. Early Initiation of Plasma Exchange Therapy for Anti-MDA5
Sasaki N; Nakagome Y; Kojima A; Shimura K; Ishii A; Sugiyama M; Izumi Y; Hirano K; Kurabayashi T; Hosono Y; Yamada C; Sato S
Intern Med; 2024 Jan; 63(2):213-219. PubMed ID: 37225493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
